* Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected
to show
no change in quarterly revenue when it reports results on May 8
(estimated).
*
* Refinitiv's mean analyst estimate for Atossa Therapeutics
Inc
is for a loss of 6 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Atossa
Therapeutics Inc is $4.75, above its last closing price
of $0.68.
This summary was machine generated May 5 at 11:53 GMT. All
figures in US dollars unless otherwise stated